First Wave BioPharma Inc - Company Profile
Powered by 
All the data and insights you need on First Wave BioPharma Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date First Wave BioPharma Inc Strategy Report
- Understand First Wave BioPharma Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
First Wave BioPharma Inc (First Wave BioPharma), formerly AzurRx BioPharma Inc, is a development-stage biopharmaceutical company that focuses on non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company's products under development include MS1819 a non-systemic yeast recombinant enzyme intended for the treatment of exocrine pancreatic insufficiency exocrine (EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP). Its pre-clinical products include AZX1103 and AZX1101 which is a recombinant beta-lactamases enzyme for the prevention of nosocomial (hospital-acquired) infections and antibiotic-associated diarrhea. The company has operations in France and the US. First Wave BioPharma is headquartered in Brooklyn, New York, the US.
Headquarters
United States of America
Address
777 Yamato Road, Suite 502, Boca Raton, Florida, 33431
Website
www.firstwavebio.com
Telephone
1 561 5897020
No of Employees
10
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
FWBI (NASD)
EPS
XYZ
Net Income (2022)
XYZ
-8%
(2022 vs 2021)
Market Cap*
$5.3M
* As of and is in US$
First Wave BioPharma Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| MS1819: |
| Exocrine Pancreatic Insufficiency associated with Chronic Pancreatitis and Cystic Fibrosis |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Acquisitions/Mergers/Takeovers | In March, the company merged with ImmunogenX. |
| 2023 | Contracts/Agreements | In December, the company entered into a non-binding term sheet to sell its Niclosamide program to treat patients with inflammatory bowel diseases (IBD) such as ulcerative colitis and related conditions. |
| 2023 | Contracts/Agreements | In September, the company entered into an agreement with Sanofi to reacquire Capeserod stages of clinical development and to commercialize the product. |
Competitor Comparison
| Key Parameters | First Wave BioPharma Inc | Johnson & Johnson | AbbVie Inc | Vertex Pharmaceuticals Inc | Protagonist Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Boca Raton | New Brunswick | North Chicago | Boston | Newark |
| State/Province | Florida | New Jersey | Illinois | Massachusetts | California |
| No. of Employees | 10 | 131,900 | 50,000 | 5,400 | 112 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| James Sapirstein | Chief Executive Officer; Chairman; President | Executive Board | 2019 | 61 |
| Sarah Romano | Chief Financial Officer | Senior Management | 2022 | - |
| James Pennington, M.D. | Chief Medical Officer | Senior Management | 2018 | 79 |
| Ted Stover | Vice President - Product Development | Senior Management | 2020 | - |
| Martin Krusin | Senior Vice President - Corporate Development | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward